Clinical trials
Recurrence clinical trials
Below are recruiting recurrence clinical trials, each written for real people, not researchers. We’re tracking 1,424 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05366179RecruitingPhase 1
Personalized CAR-T therapy for recurring brain tumor
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
Chapel Hill, North CarolinaAges 18 years+ - NCT05375370Recruiting
Testing a blood test to predict liver cancer coming back
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
RouenAges 18 years+ - NCT05407519RecruitingPhase 2
Tislelizumab and sitravatinib after liver cancer surgery to prevent relapse
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
Hefei, AnhuiAges 18–70 - NCT05408897Recruiting
Blood test to predict risk after surgery for high-risk GIST
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
Beijing, Beijing MunicipalityAges Any age - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75 - NCT05423275Recruiting
Light treatment to help you stop antidepressants safely
This study tests whether a “light and ion” treatment can help people with major depression (MDD) who are doing well on antidepressants safely reduce or stop them. You must be in remission and be willing to discontinue for reasons like side effects or personal preference.
Vancouver, British ColumbiaAges 19–65 - NCT05425004RecruitingPhase 2
Cabozantinib for recurrent or worsening meningioma tumors
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
Miami, FloridaAges 18 years+ - NCT05437965Recruiting
Registry study for repeat coronary blockages after stents
This study follows adults who have fast, unexplained re-narrowing of a coronary stent, to better understand what causes it and how to monitor it. You may help by allowing the study team to collect medical information over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT05446545Recruiting
Blood and tissue tests to monitor ovarian cancer using tumor DNA
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05465174RecruitingPhase 2
Tovorafenib for children and young adults with craniopharyngioma
This trial studies tovorafenib to treat craniopharyngioma in children and young adults. It aims to shrink the tumor or slow its growth, and to learn which patients benefit most and what side effects to expect.
Birmingham, AlabamaAges 1–39 - NCT05461820RecruitingPhase 4
Testing treatment options for Graves’ disease and its relapse
This study compares different treatment plans to see how well they control Graves’ disease and whether it comes back. It may help by identifying which approach works best to prevent relapse.
NanjingAges 18–65 - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT05474378RecruitingPhase 1
CAR T cell therapy for recurrent glioblastoma
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
Palo Alto, CaliforniaAges 18 years+ - NCT05487092Recruiting
Letrozole to help prevent endometrioma coming back after surgery
This study tests whether taking letrozole after laparoscopic ovarian cyst surgery can lower the chance that an endometrioma (a type of ovarian endometriosis cyst) comes back. It may help some people reduce recurrence after the cyst is removed.
Hong KongAges 18–45 - NCT05596630Recruiting
Stereotactic radiation for small liver cancer recurrence safety
This trial tests a precise type of radiation to treat small liver cancer that has come back after prior treatment. It aims to help with safety and long-term outcomes while protecting nearby organs and healthy liver.
Hangzhou, ZhejiangAges 18–80 - NCT05489289RecruitingPhase 3
AK104 to prevent HCC coming back after surgery
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05492136Recruiting
Radiofrequency during liver surgery to reduce cancer coming back
This study looks at whether using radiofrequency (a heat-based treatment used during surgery) during liver surgery can lower the chances that cancer returns locally. It includes people with colorectal cancer that has spread to the liver and people with liver cancer (HCC).
BarcelonaAges 18 years+ - NCT05501353Recruiting
Study tumor biomarkers in recurrent metastatic colon cancer
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
Hangzhou, ZhejiangAges 18–99 - NCT05516628RecruitingPhase 2
Adjuvant atezolizumab plus bevacizumab after liver cancer surgery
This trial studies whether adding atezolizumab and bevacizumab after complete liver cancer surgery can lower the chance the cancer comes back. It also uses “multi-omics” tests (special lab tests on your tissue/blood) to help predict who is more likely to respond or resist treatment.
SingaporeAges 21–90 - NCT05518305Recruiting
Predicting recurrent stroke risk in people with artery narrowing
This study looks at blood markers and brain/artery scan results to predict who with intracranial artery narrowing is more likely to have another stroke. It may help doctors spot higher-risk people earlier and better target prevention.
Los Angeles, CaliforniaAges 30 years+ - NCT05520034Recruiting
Nurse teaching plan to help prevent another stroke
This study tests whether nurse-led education and follow-up can lower the chance of having another stroke. It targets people who recently returned home after a first stroke and their main caregiver.
DhakaAges 18 years+ - NCT05532397Recruiting
Tested lab-chosen drug combo for recurrent brain tumor
This study uses a patient’s tumor tissue to test drug combinations in the lab, aiming to help choose a better second-line treatment for recurrent high-grade astrocytic glioma. If your tumor tissue can be tested, the results may guide a more personalized medication plan.
SingaporeAges 21–99 - NCT05557201Recruiting
Study causes of repeated early miscarriages
This study looks at people who have had repeated early pregnancy losses to find patterns that might explain why miscarriages keep happening. It mainly involves collecting and analyzing your medical information to better understand risk factors.
ParisAges 18–50
Hear when a new Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrence?
- Yes. Clin2 currently lists 1,424 recruiting recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.